LEAP THERAPEUTICS nach der KE 2019

Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital
https://www.ariva.de/news/...common-stock-purchase-agreements-7696546

424B5         https://investors.leaptx.com/node/7511/html
8K                https://investors.leaptx.com/node/7506/html  

Leap Therapeutics to Host Conference Call to Provide DKN-01 Program Update

https://www.ariva.de/news/...onference-call-to-provide-dkn-01-7727054

 

https://www.ariva.de/news/...ical-results-for-the-combination-7752548
The combination of DKN-01 and Keytruda in GEJ/GC patients demonstrated improved outcomes in patients whose tumors are DKK1-high and who were PD-1/PD-L1 naïve. DKK1-high patients experienced over 22 weeks median PFS and nearly 32 weeks OS, with a 50% ORR and 80% DCR in ten evaluable patients. DKK1-low patients experienced nearly 6 weeks median PFS and over 17 weeks OS, with a 20% DCR in fifteen evaluable patients.

PD-L1 Combined Positive Scores (CPS) did not predict efficacy on the combination of DKN-01 plus Keytruda. In multi-variate analysis, DKK1-high status correlated with longer PFS independent of PD-L1 CPS scores. One-third of patients in the study were DKK1-high.

Among the six GEJ/GC patients who were refractory to PD-1/PD-L1 therapy, three DKK1-high patients had a best response of stable disease, whereas the three patients with DKK1-low tumors had progressive disease.  

neues 52WT  

Zahlen für Q3/19

• keine Umsätze
  
• Verlust 8 Mio. $
  
• Cash 10 Mio. $
  
• MK 14 Mio. $
  
• Depriorisierung von TRX518 zugunsten von DKN-01
  

https://investors.leaptx.com/news-releases/...-2019-financial-results

https://seekingalpha.com/news/...cs-bails-2-program-shares-43-percent

 

Lizenzvereinbarung für DKN-01 mit BeiGene

https://investors.leaptx.com/news-releases/...ce-exclusive-option-and

 

• neues 52 WH
  

https://www.pharmaceutical-business-review.com/...reement-for-dkn-01/

 

Orphan Drug Designation für DKN-01

https://investors.leaptx.com/news-releases/...drug-designation-dkn-01

 

Offering im Anmarsch

https://investors.leaptx.com/news-releases/...ublic-offering-common-1

Zahlen für Q1/20

• Umsatz 0,4 Mio. $
  
• Verlust 7 Mio. $
  
• Cash 26 Mio. $
  
• MK 90 Mio. $
  

https://investors.leaptx.com/news-releases/...-2020-financial-results

 

Zahlen für Q4/20

• Umsatz 0,4 Mio. $
  
• Verlust 6,7 Mio. $
  
• Cash 52 Mio. $
  
• MK 143 Mio. $
  

https://investors.leaptx.com/news-releases/...rter-and-full-year-2020

 

 

Zahlen für Q1/21

• Umsatz 0,4 Mio. $
  
• Verlust 9,1 Mio. $
  
• Cash 43 Mio. $
  
• MK 84 Mio. $
  

https://investors.leaptx.com/news-releases/...-2021-financial-results

 

für Freitag 17.09.2021  

Zahlen für Q2/21

• Umsatz 0,4 Mio. $
  
• Verlust 10 Mio. $
  
• Cash 36 Mio. $
  
• MK 106 Mio. $
  

"We look forward to presenting initial data from the study in September, which we believe will show the important potential role DKN-01 can play for first-line gastric cancer patients, particularly those whose tumors express high levels of DKK1 where a great unmet medical need remains unaddressed."

https://investors.leaptx.com/news-releases/...-2021-financial-results

 

neue positive Daten in der DisTinGuish Studie von DKN-01 + Tislelizumab

https://investors.leaptx.com/news-releases/...sitive-data-distinguish

 

Offering im Anmarsch

https://investors.leaptx.com/news-releases/...ublic-offering-common-2

 

90 Mio. $ Offering (Stammaktien und "Pre-Funded Warrants")

• Preis 2,85$
  

https://investors.leaptx.com/news-releases/...illion-common-stock-and

 

BeiGene hält 13,2% an LPTX

Einigen sehen in LPTX schon den nächsten Übernahmekandidaten. Dem Kurs tun solche Nachrichten natürlich gut. LPTX notiert knapp unter seinem 52 WH. Sieht man momentan auch nicht so oft im Biotech-Bereich.

https://investors.leaptx.com/node/8571/html

 

LPTX kommt so langsam wieder in Regionen wo man sie auf die WL nehmen kann. MK 229 Mio. $ bei geschätzten 110 Mio. $ Cash.  

Zahlen für Q3/21

• Umsatz 0,4 Mio. $
• Verlust 11 Mio. $
• Cash 125 Mio. $
• MK 203 Mio. $

https://investors.leaptx.com/news-releases/...-2021-financial-results

 

neue Daten von DKN-01 + tislelizumab

https://investors.leaptx.com/news-releases/...-data-distinguish-study

 

Zahlen für Q4/21

• Umsatz 0,4 Mio. $
  
• Verlust 10,8 Mio. $
  
• Cash 115 Mio. $
  
• MK 132 Mio. $
  

https://investors.leaptx.com/news-releases/...rter-and-full-year-2021

Der Deal mit BGNE ist zwar auf den ersten Blick positiv, andererseits sind chinesische Unternehmen ein rotes Tuch für die USA.

 

Montoherapie gefällt mir nicht, aber ich bin kein Experte ...  

ASCO-Abstrakt

https://investors.leaptx.com/news-releases/...-investigator-sponsored

 

Zahlen für Q1/22

• keine Umsätze
  
• Verlust 10,4 Mio. $
  
• Cash 103 Mio. $
  
• MK 92 Mio. $
  

https://investors.leaptx.com/news-releases/...-2022-financial-results